The rise of Viagra and its impact on the pharmaceutical landscape presents a complex question for shareholders. While the first sales figures were astounding, the intellectual property has lapsed, leading to a deluge of off-brand alternatives that are chipping away at earnings. Moreover, the industry is facing challenges related to demographic tren